Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

On Wednesday, RFK Jr announced the US would stop funding the global vaccine alliance, Gavi, because he claimed that “when the ...

By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships.

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move signals strategic collaboration opportunities between the two companies, ...

(RTTNews) - French AI-powered biopharma company Sanofi SA (SNY) announced Tuesday it has successfully priced its offering of 1.5 billion of notes across 2 tranches. The 750 million fixed-rate ...

Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa Kirin - ResearchAndMarkets.com ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases. The drugmaker will collaborate with CSPC ...

With Enflonsia, Merck will now go up against Sanofi and AstraZeneca, which own the immunizing antibody Beyfortus. Approved in July 2023, Beyfortus has since become a top-performing asset for the ...

Pharma Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus By Kevin Dunleavy Jun 9, 2025 4:33pm Merck respiratory syncytial virus RSV Sanofi ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...